BioCardia, Inc. (OTC Pink: BCDA) is engaged in regenerative medicine treatments, particularly for cardiovascular diseases. The medical company saw shares climb 17%, during afternoon trading on Friday, December 23, 2016. Over the past three months, BioCardia, Inc. has seen average daily volume of 480,684 shares. However, volume of 467,673 shares or dollar volume of $289,957, has already exchanged hands in the final trading session before the Christmas weekend.
Shares of BioCardia, Inc. are rallying today, after the company announced that it has received a U.S. patent for its regenerative treatments for myocardial infarcts. This is the second U.S. patent that BioCardia, Inc. has been awarded in the past two weeks. Here is the full press release detailing of the U.S. patent:
BioCardia, Inc. Press Release:
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure and sub-acute infarction, today announced the issuance of United States Patent No. 9,517,199 relating to a method of delivering cells to patients who have chronic myocardial infarcts. This new patent follows United States Patent No. 9,504,642, issued to BioCardia two weeks ago. Dr. Peter Altman, CEO of BioCardia: “We are pleased to have obtained this additional new patent which provides further protection around our CardiAMP program. Our patent strategy is to pursue protection around our active programs where we are investing our resources.”
About BioCardia, Inc.:
BioCardia, Inc., headquartered in San Carlos, CA, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP® and CardiALLO® cell therapies are the company’s biotherapeutic product candidates in clinical development. The Company’s current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.